Mylan Discloses its Previous Acquisition of Worldwide Rights to Commercialize Novartis’ Products for $463M

Shots:

•  Mylan reveals its undisclosed agreement signed on 30 July, 2018 for worldwide commercialization rights for Novartis’ global cystic fibrosis products,TOBI Podhaler and TOBI solution
•  Company also revealed the reason for keeping the deal undisclosed, as the transaction was under pre-closing confidentiality restrictions
• The focus of the purchase is to enrich its respiratory units in US, EU and in certain worldwide markets. The transaction is expected to be paid in H2’18 with ~ $240M of $463M

Click here to read full press release/ article | Ref: Mylan | Image:  Fortune